A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

Inclusion Criteria:

1. Voluntary signing of a written informed consent form.

2. Age between 18 and 70 years.

3. Histologically or cytologically confirmed locally advanced or metastatic solid tumorpatients who are not amenable to surgical resection, with no standard treatmentoptions, or who have relapsed or progressed after standard treatment, or areresistant or intolerant to standard treatment.

4. At least one assessable tumor lesion according to Response Evaluation Criteria inSolid Tumors, version 1.1 (RECIST 1.1).

5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

6. Expected survival ≥12 weeks.

7. Must have adequate bone marrow, liver, and renal function.

Exclusion Criteria:

1. Insufficient washout period for prior anti-tumor treatments before the first dose,including chemotherapy, targeted therapy, antibody therapy, and radiotherapy.

2. Participation in another clinical trial and use of investigational drugs within 28days before the first dose.

3. Requirement for anticoagulation therapy.

4. Symptomatic brain parenchymal metastases with less than 4 weeks of stability aftertreatment.

5. Active pulmonary diseases, including but not limited to interstitial lung disease,pneumonitis.

6. Uncontrolled active infections.

7. Uncontrollable massive pleural effusion, ascites, or pericardial effusion.

8. Previous receipt of other cellular therapies.

9. Planned concurrent participation in other anti-tumor treatments during the study.

10. Pregnant or breastfeeding women.